利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

43 条记录 (耗时 0.05 秒)

    PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN ENCODING RNA
    6.
    发明申请
    PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN ENCODING RNA 审中-公开
    用于递送免疫原编码RNA的聚乙二醇化脂质体

    公开(公告)号：US20130202684A1

    公开(公告)日：2013-08-08

    申请号：US13819077

    申请日：2011-08-31

    申请人： Andrew Geall ,  Ayush Verma

    发明人： Andrew Geall ,  Ayush Verma

    IPC分类号： A61K9/127

    CPC分类号： A61K9/127 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/1271 ,  A61K39/12 ,  A61K39/155 ,  A61K39/39 ,  A61K2039/53 ,  A61K2039/55505 ,  A61K2039/55555 ,  C12N15/88 ,  C12N2710/16134 ,  C12N2760/18534 ,  C12N2770/36143 ,  C12N2770/36171

    摘要： Nucleic acid immunisation is achieved by delivering RNA encapsulated within a PEGylated liposome. The RNA encodes an immunogen of interest. The PEG has an average molecular mass of between 1 kDa and 3 kDa. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer comprises at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is between 1 kDa and 3 kDa; and (ii) the aqueous core includes a RNA which encodes an immunogen. These liposomes are suitable for in vivo delivery of the RNA to a vertebrate cell and so they are useful as components in pharmaceutical compositions for immunising subjects against various diseases.

    摘要翻译： 通过递送封装在聚乙二醇化脂质体内的RNA来实现核酸免疫。 RNA编码感兴趣的免疫原。 PEG具有1kDa至3kDa的平均分子量。 因此，本发明提供了一种脂质体，其具有包封水性核心的脂质双层，其中：（i）脂质双层包含至少一种包含聚乙二醇部分的脂质，使得聚脂二醇存在于脂质体外部，其中平均分子量 聚乙二醇的质量在1kDa和3kDa之间; 和（ii）含水核心包括编码免疫原的RNA。 这些脂质体适合于将体内的RNA递送至脊椎动物细胞，因此它们可用作免疫各种疾病的受试者的药物组合物中的组分。

    LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN CODING RNA
    7.
    发明申请
    LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN CODING RNA 审中-公开
    适用于蛋白质编码RNA的脂质体递送的脂蛋白

    公开(公告)号：US20130189351A1

    公开(公告)日：2013-07-25

    申请号：US13819228

    申请日：2011-08-31

    申请人： Andrew Geall

    发明人： Andrew Geall

    IPC分类号： A61K9/127 ,  A61K39/155

    摘要： RNA is encapsulated within a liposome for in vivo delivery. The RNA encodes a polypeptide of interest, such as an immunogen for immunisation purposes. The liposome includes at least one compound selected from the group consisting of compounds of formula (I) and formula (XI).

    摘要翻译： RNA被包封在脂质体内用于体内递送。 RNA编码感兴趣的多肽，例如用于免疫目的的免疫原。 脂质体包括至少一种选自式（I）和式（XI）的化合物的化合物。

    Method for producing sterile polynucleotide based medicaments
    9.
    发明授权
    Method for producing sterile polynucleotide based medicaments 失效
    用于生产基于无菌多核苷酸的药物的方法

    公开(公告)号：US08435557B2

    公开(公告)日：2013-05-07

    申请号：US12109944

    申请日：2008-04-25

    申请人： Joel Enas ,  Andrew Geall

    发明人： Joel Enas ,  Andrew Geall

    IPC分类号： A61K9/127 ,  A61K47/30 ,  C07H21/04 ,  C08K5/07

    CPC分类号： C07C219/14 ,  A61K9/1075 ,  C07C211/63 ,  C07C217/28 ,  C07C219/06 ,  Y10S977/797

    摘要： The present invention relates to a novel method for producing formulations comprising a polynucleotide, block copolymer and cationic surfactant. The formulations produced by the current method are suitable for use in polynucleotide based medicaments. A suitable method of production disclosed herein additionally comprises cold filtering a mixture of a polynucleotide, block copolymer and cationic surfactant, thereby sterilizing the formulation. The method of the present invention also eliminates the need for thermal cycling of the formulation, thereby reducing the time and expense required to produce large quantities of a formulation during commercial manufacturing. The present invention also relates to novel cationic lipids.

    摘要翻译： 本发明涉及一种制备包含多核苷酸，嵌段共聚物和阳离子表面活性剂的制剂的新方法。 通过当前方法制备的制剂适用于基于多核苷酸的药物。 本文公开的合适的生产方法另外包括冷过滤多核苷酸，嵌段共聚物和阳离子表面活性剂的混合物，从而对制剂灭菌。 本发明的方法也消除了对制剂的热循环的需要，从而减少在商业制造过程中生产大量制剂所需的时间和费用。 本发明还涉及新型阳离子脂质。

    Influenza virus vaccine composition and methods of use
    10.
    发明申请
    Influenza virus vaccine composition and methods of use 有权
    流感病毒疫苗组合物及使用方法

    公开(公告)号：US20080057080A1

    公开(公告)日：2008-03-06

    申请号：US11715973

    申请日：2007-03-09

    申请人： Catherine Luke ,  Adrian Vilalta ,  Mary Wloch ,  Thomas Evans ,  Andrew Geall ,  Gretchen Jimenez

    发明人： Catherine Luke ,  Adrian Vilalta ,  Mary Wloch ,  Thomas Evans ,  Andrew Geall ,  Gretchen Jimenez

    IPC分类号： A61K39/145 ,  A61K31/7105 ,  A61P31/12 ,  C07H21/02 ,  C12N15/85

    CPC分类号： C12N7/00 ,  A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/55511 ,  A61K2039/55555 ,  A61K2039/55566 ,  A61K2039/70 ,  C07K16/1018 ,  C07K2317/34 ,  C12N2760/16134 ,  C12N2760/16151

    摘要： The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to enhancing the immune response of a human in need of protection against IV infection by administering, in vivo, into a tissue of the human, at least one IV protein or a fragment, a variant, or derivative thereof. The IV protein can be, for example, in purified form or can be an inactivated IV, such as those present in inactivated IV vaccines. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo. The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount.

    摘要翻译： 本发明涉及通过在体内施用人体组织来增强需要防止IV感染的人的免疫应答，所述至少一种多核苷酸包含一个或多个编码IV蛋白的核酸区域或 片段，变体或其衍生物。 本发明进一步涉及通过在体内施用人体组织，至少一种IV蛋白或其片段，变体或衍生物来增强需要保护免受IV感染的人的免疫应答。 IV蛋白可以是例如纯化形式或可以是灭活的IV，例如存在于灭活IV疫苗中的那些。 将多核苷酸体内并入人的细胞中，并且在体内产生免疫有效量的IV或其片段，变体或衍生物的免疫原性表位。 IV蛋白（以纯化形式或灭活IV疫苗的形式）也以免疫有效量施用。